Trial Profile
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Panobinostat (Primary) ; Dexamethasone
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions
- 14 Jan 2019 Status changed from active, no longer recruiting to completed.
- 20 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 01 Dec 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.